# The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults

Study · id `cardio:ct-nct06224296` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06224296](<https://clinicaltrials.gov/study/NCT06224296>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06224296

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06224296. Allocation not applicable; no masking; primary purpose prevention. Start 2024-03-01 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06224296, source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)
- Planned start: 2024-03-01 (anticipated) (ClinicalTrials.gov record NCT06224296, source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT06224296, source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)
- Completion: 2025-03-01 (anticipated) (ClinicalTrials.gov record NCT06224296, source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06224296, source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06224296-2024-01-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
- Condition: Sub-healthy
- Condition: Hyperlipidemia
- Condition: Toxic Metal Ions Accumulation
- Intervention (Device): DFPP
- Intervention (Device): DFPP
- Intervention (Device): DFPP
- Lead sponsor: Shanghai Cell Therapy Group Co.,Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Shanghai Mengchao Cancer Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 3d77120f6b95519534e0223b25ba9bdaf8a7f6fbbbd7d2007947027553f731cf
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
